AAV Production Using Baculovirus Expression Vector System
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Gene transfer and gene therapy are powerful approaches for many biological research applications and promising avenues for the treatment of many genetic or cancer diseases. The most efficient gene transfer tools are currently derived from viruses. Among them, the recombinant adeno-associated viruses (AAVs) are vectors of choice for many fundamental and therapeutic applications. The increasing number of clinical trials involving AAVs demonstrates the need to implement production and purification processes to meet the quantitative and qualitative demands of regulatory agencies for the use of these vectors in clinical trials. In this context, the rise of production levels on an industrial scale appeared essential. The introduction, in 2002, of an AAV process using a baculovirus expression vector system (BEVS) has circumvented this technological lock. The advantage of BEVS in expanding the AAV production in insect cells has been to switch the process to bioreactor systems, which are the ideal equipment for scaling up. We describe here a method for producing AAV vectors using the BEVS which can be easily used by research laboratories wishing to overcome the difficulties associated with the scaling up of production levels. The method provides sufficient quantities of AAV vectors to initiate preclinical projects in large animal models or for research projects where a single batch of vectors will consolidate the repeatability and reproducibility of in vitro and especially in vivo exp…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third, the production of AAV at scale and the employment of good manufacturing process (GMP) methods at affordable cost for clinical use remains a formidable challenge 68-70 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [69]
Citations
Cites
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors
Grimm, D., Kern, A., Rittner, K., & Kleinschmidt, J. A. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.18-2745 · Cited by 696
Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors
Urabe, M., Ding, C., & Kotin, R. M. (2002) · Human Gene Therapy · doi:10.1089/10430340260355347 · Cited by 457
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Factors Influencing Recombinant Adeno-Associated Virus Production
Salvetti, A., Orève, S., Chadeuf, G., Favre, D., Cherel, Y., Champion-Arnaud, P., David-Ameline, J., & Moullier, P. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.5-695 · Cited by 241
Wasilko, D. J., Lee, S. E., Stutzman-Engwall, K. J., Reitz, B. A., Emmons, T. L., Mathis, K. J., Bienkowski, M. J., Tomasselli, A. G., & Fischer, H. (2009) · Protein Expression and Purification · doi:10.1016/j.pep.2009.01.002 · Cited by 118
Chahal, P. S., Schulze, E., Tran, R., Montes, J., & Kamen, A. A. (2014) · Journal of Virological Methods · doi:10.1016/j.jviromet.2013.10.038 · Cited by 111
Cecchini, S., Virag, T., & Kotin, R. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.250 · Cited by 97
Martin, J., Frederick, A., Luo, Y., Jackson, R., Joubert, M., Sol, B., Poulin, F., Pastor, E., Armentano, D., Wadsworth, S., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.046 · Cited by 79
Dias Florencio, G., Precigout, G., Beley, C., Buclez, P.-O., Garcia, L., & Benchaouir, R. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.24 · Cited by 32
Self-citation
Cited by
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
“The rBac/Sf9 system has advantages in yield, empty/full ratio, and scalability over other systems (50, 51).”
BackgroundT Cell-Mediated Immune Responses to AAV and AAV Vectors
Ertl, H. C. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666666 · Cited by 88
Strategies for Optimizing the Production of Proteins and Peptides with Multiple Disulfide Bonds
Ma, Y., Lee, C.-J., & Park, J.-S. (2020) · Antibiotics · doi:10.3390/antibiotics9090541 · Cited by 71
Ramírez, C. M., Cifuentes, J., Castellanos, M. C., Moreno, R. J., Muñoz-Camargo, C., Cruz, J. C., & Reyes, L. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060561 · Cited by 51
Metadata
- Authors
- Sandro, Q., Relizani, K., & Benchaouir, R.
- Affiliations
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Corresponding author
- Benchaouir, Rachid
- ORCID
- Relizani, Karima
- Venue
- Methods in Molecular Biology
- Publisher
- Springer New York
- Published
- 2019
- Volume
- 1937
- Pages
- 91-99
- ISSN
- 1064-3745 (ISSN-L)
- 1940-6029
- OpenAlex
- W2913285001
- Cited by
- 24
- References
- 12
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 8 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 5 · 2019: 1
- FWCI
- 3.57
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Methods in molecular biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- recombinant adeno-associated virus, AAV production, baculovirus expression system, insect cell expression, bioreactor scale-up, gene therapy vectors, vector purification
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Virus Cultivation, Reproducibility of Results, Gene Expression, Cryopreservation, Baculoviridae, Gene Transfer Techniques, Sf9 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AAV Production Using Baculovirus Expression Vector System. https://app.cochat.ai/papers/10.1007/978-1-4939-9065-8_5
- The paper
- Sandro, Q., Relizani, K., & Benchaouir, R. (2019). AAV Production Using Baculovirus Expression Vector System. Methods in Molecular Biology. https://doi.org/10.1007/978-1-4939-9065-8_5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.